Research and development of Zika virus vaccines

Brian E. Dawes, Claire A. Smalley, Bethany L. Tiner, David Beasley, Gregg Milligan, Lisa M. Reece, Joachim Hombach, Alan Barrett

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Zika virus (ZIKV) is a member of the family Flaviviridae, genus Flavivirus, and is transmitted by Aedes sp. mosquitoes. There are three genetic lineages of ZIKV: the East African, West African and Asian lineages. Until recently, Zika fever (ZF) has normally been considered a rare, mild febrile disease, but reports since 2012 have shown potentially severe complications associated with ZIKV infection, including microcephaly and Guillain-Barré syndrome. There are no licensed vaccines for ZIKV; however, many vaccine platforms/approaches that have been utilised for other flavivirus vaccines are being applied to ZIKV. Given the current outbreak of ZIKV in the Americas with its associated risks to pregnancy, we summarise what is known about the virus, how knowledge of currently licensed flavivirus vaccines can be applied to ZIKV vaccine development and the assessments of potential challenges for ZIKV vaccine testing and evaluation.

Original languageEnglish (US)
Article number16007
Journalnpj Vaccines
Volume1
DOIs
StatePublished - Jul 28 2016

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Immunology
  • Pharmacology (medical)

Cite this